Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis

被引：0
|
作者：
Zhang, Peng-Fei [1 ,2 ,3 ,4 ]
Wen, Feng [1 ,2 ]
Wu, Qiu-Ji [1 ,2 ]
Li, Qiu [1 ,2 ]
机构：
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu 610041, Peoples R China
[2] Sichuan Univ, Med X Ctr Informat, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Hosp, Lab Human Dis & Immunotherapies, Chengdu 610041, Peoples R China
[4] Sichuan Univ, West China Hosp, Frontiers Sci Ctr Dis Related Mol Network, Inst Immunol & Inflammat, Chengdu 610041, Peoples R China
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2022年 / 11卷 / 14期
关键词：
atezolizumab; chemotherapy; cost-effectiveness; first-line; urothelial cancer; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; CARCINOMA; COMBINATION; PEMBROLIZUMAB; METHOTREXATE; VINBLASTINE; GEMCITABINE; CARBOPLATIN;
D O I：
10.2217/cer-2022-0064
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Purpose: To evaluate the cost-effectiveness of atezolizumab plus chemotherapy as first-line treatment for metastatic urothelial cancer (mUC). Materials & methods: A Markov model was established for the analysis. Parametric survival models were used to fit to progression-free survival and overall survival data in the IMvigor130 study. A series of one-way and probabilistic sensitivity analyses were performed to test the robustness of the model. Results: The incremental cost-effectiveness ratios for atezolizumab plus chemotherapy versus chemotherapy alone were US$475,633.17 and $207,488.17 per quality-adjusted life year in the USA and China, respectively. Utility for the progression-free survival and progressive disease states, the cost of atezolizumab had the most significant impact on the incremental cost-effectiveness ratio. Conclusion: Atezolizumab plus chemotherapy is not a cost-effective treatment option as a first-line treatment for metastatic urothelial cancer.
引用
收藏
页码：1021 / 1030
页数：10
相关论文
共 50 条
  • [1] Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
    Qin, Shuxia
    Yi, Lidan
    Li, Sini
    Tan, Chongqing
    Zeng, Xiaohui
    Wang, Liting
    Peng, Ye
    Wan, Xiaomin
    [J]. ADVANCES IN THERAPY, 2021, 38 (06) : 3399 - 3408
  • [2] Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
    Shuxia Qin
    Lidan Yi
    Sini Li
    Chongqing Tan
    Xiaohui Zeng
    Liting Wang
    Ye Peng
    Xiaomin Wan
    [J]. Advances in Therapy, 2021, 38 : 3399 - 3408
  • [3] Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
    Liu, Xiaoyan
    Lang, Yitian
    Chai, Qingqing
    Lin, Yan
    Liao, Yahui
    Zhu, Yizhun
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
  • [5] Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer
    Villa, D.
    Hedden, L.
    Peacock, S.
    Kennecke, H. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
    Attard, C. L.
    Brown, S.
    Alloul, K.
    Moore, M. J.
    [J]. CURRENT ONCOLOGY, 2014, 21 (01) : E41 - E51
  • [7] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    [J]. ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
  • [8] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Dong Ding
    Huabin Hu
    Mengting Liao
    Yin Shi
    Longjiang She
    Linli Yao
    Youwen Zhu
    Shan Zeng
    Jin Huang
    [J]. Advances in Therapy, 2020, 37 : 2116 - 2126
  • [9] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China.
    Li, Lingyu
    Wang, Hong
    Li, Wenqian
    Cui, Jiuwei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345